Isosteviol ameliorates diabetic cardiomyopathy in rats by inhibiting ERK and NF-κB signaling pathways.

Autor:	Tang SG; School of Bioscience and BioengineeringSouth China University of Technology, Guangzhou, China., Liu XY; School of Bioscience and BioengineeringSouth China University of Technology, Guangzhou, China., Ye JM; Molecular Pharmacology for DiabetesSchool of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia., Hu TT; School of Bioscience and BioengineeringSouth China University of Technology, Guangzhou, China., Yang YY; School of Bioscience and BioengineeringSouth China University of Technology, Guangzhou, China., Han T; School of Bioscience and BioengineeringSouth China University of Technology, Guangzhou, China., Tan W; Institute of Biomedical & Pharmaceutical ScienceGuangdong University of Technology, Guangzhou, China went@gdut.edu.cn.
Jazyk:	angličtina
Zdroj:	The Journal of endocrinology [J Endocrinol] 2018 Jul; Vol. 238 (1), pp. 47-60. Date of Electronic Publication: 2018 May 02.
DOI:	10.1530/JOE-17-0681
Abstrakt:	Diabetes-induced injury of myocardium, defined as diabetic cardiomyopathy (DCM), accounts for significant mortality and morbidity in diabetic population. Alleviation of DCM by a potent drug remains considerable interests in experimental and clinical researches because hypoglycemic drugs cannot effectively control this condition. Here, we explored the beneficial effects of isosteviol sodium (STVNa) on type 1 diabetes-induced DCM and the potential mechanisms involved. Male Wistar rats were induced to diabetes by injection of streptozotocin (STZ). One week later, diabetic rats were randomly grouped to receive STVNa (STZ/STVNa) or its vehicle (STZ). After 11 weeks of treatment or 11 weeks treatment following 4 weeks of removal of the treatment, the cardiac function and structure were evaluated and related mechanisms were investigated. In diabetic rats, oxidative stress, inflammation, blood glucose and plasma advanced glycation end products (AGEs) were significantly increased, whereas superoxide dismutase 2 (SOD-2) expression and activity were decreased. STVNa treatment inhibited cardiac hypertrophy, fibrosis and inflammation, showed similar ratio of heart to body weight and antioxidant capacities almost similar to the normal controls, which can be sustained at least 4 weeks. Moreover, STVNa inhibited diabetes-inducted stimulation of both extracellular signal-regulated kinase (ERK) and nuclear factor κB (NF-κB) signal pathways. However, blood glucose, plasma AGE and insulin levels were not altered by STVNa treatment. These results indicate that STVNa may be developed into a potent therapy for DCM. The mechanism underlying this therapeutic effect involves the suppression of oxidative stress and inflammation by inhibiting ERK and NF-κB without changing blood glucose or AGEs. (© 2018 Society for Endocrinology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu